Dr. Charles R. Powell JR., M.D.
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 294
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Indiana University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
IN license 01066313A · IA license 37723 · IL license 125044893
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
- Eskenazi Health Indianapolis, IN
- Indiana University Health Arnett Hospital Lafayette, IN
- Indiana University Health North Hospital Carmel, IN
- Iu Health West Hospital Avon, IN
Medical groups
- Iu Health Medical Group LLC (4,462 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 294
- Services billed
- 1,424
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 96 | 90 |
| Established patient office or other outpatient visit, 30-39 minutes | 75 | 71 |
| Diagnostic exam of bladder and urethra using an endoscope | 46 | 39 |
| Ultrasound measurement of bladder capacity after voiding | 41 | 35 |
| Electronic assessment of bladder emptying | 37 | 35 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 33 | 32 |
| Insertion of device into abdomen with pressure and urine flow rate study | 33 | 32 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 28 | 23 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 25 | 15 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Indianapolis, IN | 70 |
| Myrbetriq (mirabegron) Other prescribers in Indianapolis, IN | 70 |
| Nitrofurantoin Mono-Macro (nitrofurantoin monohyd/m-cryst) Other prescribers in Indianapolis, IN | 62 |
| Diclofenac Potassium Other prescribers in Indianapolis, IN | 56 |
| Gemtesa (vibegron) Other prescribers in Indianapolis, IN | 52 |
| Cephalexin Other prescribers in Indianapolis, IN | 46 |
| Finasteride Other prescribers in Indianapolis, IN | 43 |
| Acetic Acid | 34 |
| Estradiol Other prescribers in Indianapolis, IN | 34 |
| Elmiron (pentosan polysulfate sodium) | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 16 payments worth $546 in total to this clinician.
| Boston Scientific Corporation | $310 |
|---|---|
| Medtronic, Inc. | $158 |
| Urogen Pharma, Inc. | $41.66 |
| AstraZeneca Pharmaceuticals LP | $35.06 |
| Food and Beverage | $510 |
|---|---|
| Education | $35.06 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $35.06 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $580 in research payments for these studies, mostly to the institutions running them.
- PEER 2
Medtronic, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.